HIV-1 Protease Inhibitors (Janssen Therapeutics/Medivir)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameHIV-1 Protease Inhibitors (Janssen Therapeutics/Medivir)
Drug Alias Nameprotease inhibitor (Medivir/Tibotec)HIV-PI
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHuman immunodeficiency virus type 1 protease inhibitors
TargetsHuman immunodeficiency virus type 1 protease
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSweden
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMedivir AB
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMedivir AB +[2] 
Active IndicationsN/A
Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A
Related LinksN/A